The Alzheimer’s Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science and clinical practice. Each year, AAIC convenes researchers, clinicians, and dementia professionals from all
Alzheimer’s Association International Conference (AAIC) Highlights Read More »
First Choice Neurology, the largest neurology group in the United States, is set to make medical history this week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the
First Choice Neurology Administers New Alzheimer’s Drug Kisunla Read More »
Are you familiar with Kisunla, the newly FDA-approved medication for Alzheimer’s disease? The Food and Drug Administration approved Lilly’s Kisunla (donanemab) earlier this week for mild or early cases of
KISUNLA: The NEW Alzheimer’s FDA Approved Medication Read More »
New Alzheimer’s drugs may benefit whites more than black Americans, leading Alzheimer’s experts told Reuters. Leqembi and donanemab are the first Alzheimer’s drugs to offer real hope of slowing cognitive
New Alzheimer’s Drugs May Benefit Whites More Than Blacks Read More »
June is an important month for raising awareness about Alzheimer’s disease and promoting brain health. This year, Alzheimer’s & Brain Awareness Month brings exceptional news for those affected by this
According to a study led by researchers at UCLA, the Alzheimer’s drug Leqembi would raise future costs for Medicare by $2 billion to $5 billion a year. Leqembi, sold for
Study finds Alzheimer’s drug Leqembi would cost Medicare up to $5 billion a year Read More »
The MIND diet was developed in 2015 by Rush University nutritional epidemiologist Martha Clare Morris and her colleagues. The MIND diet is a scientifically proven eating plan that aims to
MIND Diet Helps to Prevent Dementia and Alzheimer’s Disease Read More »
The FDA approved the new Alzheimer’s drug lecanemab (BAN2401), which will be sold under the brand name Leqembi developed by Eisai and Biogen last week for patients with mild cognitive
First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 50 Care Centers in six Florida counties and services at 45+ major hospitals, has become the
First Choice Neurology to Offer New Alzheimer’s Risk Test Read More »
Biogen is providing its new Alzheimer’s drug, Aduhelm, free to some patients due to slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab,
Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »
